Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

YC. Foong, D. Merlo, M. Gresle, K. Buzzard, M. Zhong, WZ. Yeh, V. Jokubaitis, M. Monif, O. Skibina, S. Ozakbas, F. Patti, P. Grammond, MP. Amato, T. Kalincik, D. Horakova, E. Kubala Havrdova, B. Weinstock-Guttman, J. Lechner Scott, C. Boz, MJ....

. 2024 ; 95 (8) : 767-774. [pub] 20240715

Language English Country England, Great Britain

Document type Journal Article, Comparative Study, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24019746
E-resources Online Full text

NLK ProQuest Central from 1944-07-01 to 6 months ago
Nursing & Allied Health Database (ProQuest) from 1944-07-01 to 6 months ago
Health & Medicine (ProQuest) from 1944-07-01 to 6 months ago
Psychology Database (ProQuest) from 1944-07-01 to 6 months ago

Links

PubMed 38453478
DOI 10.1136/jnnp-2023-332883
Knihovny.cz E-resources

BACKGROUND: Ongoing controversy exists regarding optimal management of disease modifying therapy (DMT) in older people with multiple sclerosis (pwMS). There is concern that the lower relapse rate, combined with a higher risk of DMT-related infections and side effects, may alter the risk-benefit balance in older pwMS. Given the lack of pwMS above age 60 in randomised controlled trials, the comparative efficacy of high-efficacy DMTs such as ocrelizumab has not been shown in older pwMS. We aimed to evaluate the comparative effectiveness of ocrelizumab, a high-efficacy DMT, versus interferon/glatiramer acetate (IFN/GA) in pwMS over the age of 60. METHODS: Using data from MSBase registry, this multicentre cohort study included pwMS above 60 who switched to or started on ocrelizumab or IFN/GA. We analysed relapse and disability outcomes after balancing covariates using an inverse probability treatment weighting (IPTW) method. Propensity scores were obtained based on age, country, disease duration, sex, baseline Expanded Disability Status Scale, prior relapses (all-time, 12 months and 24 months) and prior DMT exposure (overall number and high-efficacy DMTs). After weighting, all covariates were balanced. Primary outcomes were time to first relapse and annualised relapse rate (ARR). Secondary outcomes were 6-month confirmed disability progression (CDP) and confirmed disability improvement (CDI). RESULTS: A total of 248 participants received ocrelizumab, while 427 received IFN/GA. The IPTW-weighted ARR for ocrelizumab was 0.01 and 0.08 for IFN/GA. The IPTW-weighted ARR ratio was 0.15 (95% CI 0.06 to 0.33, p<0.001) for ocrelizumab compared with IFN/GA. On IPTW-weighted Cox regression models, HR for time to first relapse was 0.13 (95% CI 0.05 to 0.26, p<0.001). The hazard of first relapse was significantly reduced in ocrelizumab users after 5 months compared with IFN/GA users. However, the two groups did not differ in CDP or CDI over 3.57 years. CONCLUSION: In older pwMS, ocrelizumab effectively reduced relapses compared with IFN/GA. Overall relapse activity was low. This study adds valuable real-world data for informed DMT decision making with older pwMS. Our study also confirms that there is a treatment benefit in older people with MS, given the existence of a clear differential treatment effect between ocrelizumab and IFN/GA in the over 60 age group.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019746
003      
CZ-PrNML
005      
20241024110956.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jnnp-2023-332883 $2 doi
035    __
$a (PubMed)38453478
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Foong, Yi Chao $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia $u Department of Neurology, Tasmanian Health Service, Hobart, Tasmania, Australia $1 https://orcid.org/000000016447078X
245    10
$a Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 / $c YC. Foong, D. Merlo, M. Gresle, K. Buzzard, M. Zhong, WZ. Yeh, V. Jokubaitis, M. Monif, O. Skibina, S. Ozakbas, F. Patti, P. Grammond, MP. Amato, T. Kalincik, D. Horakova, E. Kubala Havrdova, B. Weinstock-Guttman, J. Lechner Scott, C. Boz, MJ. Sa, H. Butzkueven, A. van der Walt, C. Zhu, MSBASE study group
520    9_
$a BACKGROUND: Ongoing controversy exists regarding optimal management of disease modifying therapy (DMT) in older people with multiple sclerosis (pwMS). There is concern that the lower relapse rate, combined with a higher risk of DMT-related infections and side effects, may alter the risk-benefit balance in older pwMS. Given the lack of pwMS above age 60 in randomised controlled trials, the comparative efficacy of high-efficacy DMTs such as ocrelizumab has not been shown in older pwMS. We aimed to evaluate the comparative effectiveness of ocrelizumab, a high-efficacy DMT, versus interferon/glatiramer acetate (IFN/GA) in pwMS over the age of 60. METHODS: Using data from MSBase registry, this multicentre cohort study included pwMS above 60 who switched to or started on ocrelizumab or IFN/GA. We analysed relapse and disability outcomes after balancing covariates using an inverse probability treatment weighting (IPTW) method. Propensity scores were obtained based on age, country, disease duration, sex, baseline Expanded Disability Status Scale, prior relapses (all-time, 12 months and 24 months) and prior DMT exposure (overall number and high-efficacy DMTs). After weighting, all covariates were balanced. Primary outcomes were time to first relapse and annualised relapse rate (ARR). Secondary outcomes were 6-month confirmed disability progression (CDP) and confirmed disability improvement (CDI). RESULTS: A total of 248 participants received ocrelizumab, while 427 received IFN/GA. The IPTW-weighted ARR for ocrelizumab was 0.01 and 0.08 for IFN/GA. The IPTW-weighted ARR ratio was 0.15 (95% CI 0.06 to 0.33, p<0.001) for ocrelizumab compared with IFN/GA. On IPTW-weighted Cox regression models, HR for time to first relapse was 0.13 (95% CI 0.05 to 0.26, p<0.001). The hazard of first relapse was significantly reduced in ocrelizumab users after 5 months compared with IFN/GA users. However, the two groups did not differ in CDP or CDI over 3.57 years. CONCLUSION: In older pwMS, ocrelizumab effectively reduced relapses compared with IFN/GA. Overall relapse activity was low. This study adds valuable real-world data for informed DMT decision making with older pwMS. Our study also confirms that there is a treatment benefit in older people with MS, given the existence of a clear differential treatment effect between ocrelizumab and IFN/GA in the over 60 age group.
650    _2
$a lidé $7 D006801
650    12
$a glatiramer acetát $x terapeutické užití $7 D000068717
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $x škodlivé účinky $7 D061067
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a imunologické faktory $x terapeutické užití $x škodlivé účinky $7 D007155
650    _2
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    _2
$a výsledek terapie $7 D016896
650    _2
$a kohortové studie $7 D015331
650    _2
$a interferony $x terapeutické užití $x škodlivé účinky $7 D007372
650    _2
$a recidiva $7 D012008
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Merlo, Daniel $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Eastern Health, Box Hill, Victoria, Australia
700    1_
$a Gresle, Melissa $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia $u Melbourne Health, Melbourne, Victoria, Australia
700    1_
$a Buzzard, Katherine $u Eastern Health, Box Hill, Victoria, Australia $u Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
700    1_
$a Zhong, Michael $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia
700    1_
$a Yeh, Wei Zhen $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia
700    1_
$a Jokubaitis, Vilija $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia $1 https://orcid.org/0000000239424340
700    1_
$a Monif, Mastura $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia
700    1_
$a Skibina, Olga $u Alfred Health, Melbourne, Victoria, Australia $u Eastern Health, Box Hill, Victoria, Australia
700    1_
$a Ozakbas, Serkan $u Medical Point Hospital, Izmir, Turkey
700    1_
$a Patti, Francesco $u Neuroscience, University of Catania Department of Surgical and Medical Sciences and Advanced Technologies 'G.F. Ingrassia', Catania, Italy $u University of Catania, Catania, Italy $1 https://orcid.org/0000000269230846
700    1_
$a Grammond, Pierre $u Hotel-Dieu de Levis, Levis, Quebec, Canada
700    1_
$a Amato, Maria Pia $u Department of Neurological Siences, University of Florence, Florence, Italy
700    1_
$a Kalincik, Tomas $u Department of Neurology, The Royal Melbourne Hospital, Parkville, Victoria, Australia $u CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia $1 https://orcid.org/0000000337781376 $7 xx0121848
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Kubala Havrdova, Eva $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Weinstock-Guttman, Bianca $u Neurology, Jacobs Comprehensive MS Treatment and Research Center, Buffalo, New York, USA
700    1_
$a Lechner Scott, Jeanette $u Hunter New England Health, New Lambton, New South Wales, Australia $u The University of Newcastle, Newcastle, New South Wales, Australia
700    1_
$a Boz, Cavit $u Karadeniz Technical University, Trabzon, Turkey
700    1_
$a Sa, Maria Jose $u Neurology, Centro Hospitalar de São João, Porto, Portugal $u Faculty of Health Sciences University Fernando Pessoa, Porto, Portugal
700    1_
$a Butzkueven, Helmut $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $u Alfred Health, Melbourne, Victoria, Australia
700    1_
$a van der Walt, Anneke $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia anneke.vanderwalt@monash.edu $u Alfred Health, Melbourne, Victoria, Australia $1 https://orcid.org/0000000242787003
700    1_
$a Zhu, Chao $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia $1 https://orcid.org/0000000339517501
710    2_
$a MSBASE study group
773    0_
$w MED00010064 $t Journal of neurology, neurosurgery, and psychiatry $x 1468-330X $g Roč. 95, č. 8 (2024), s. 767-774
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38453478 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110950 $b ABA008
999    __
$a ok $b bmc $g 2202147 $s 1231719
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 95 $c 8 $d 767-774 $e 20240715 $i 1468-330X $m Journal of neurology, neurosurgery, and psychiatry $n J Neurol Neurosurg Psychiatry $x MED00010064
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options